Troponin HsTnI as pronostic factor in Covid-19 patients : Mohammed VI Hospital University experience

Background Recent reports have demonstrated high troponin levels in patients affected with COVID-19. We sought in our study to determine the relationship between troponin levels and COVID-19 outcomes severity/mortality.

This was an observational retrospective cohort study of 325 patients admitted and diagnosed COVID-19 positive in Mohammed VI CHU in Oujda from July 2021 to November 2021

The mean age between deceased and cured patients (68.92 ± 15.06 vs 62.5 ± 15.73 years, respectively, p<0.001) but no significant difference in the sex ratio was found in the two groups (p 0.379). 191 on admission, had a measured troponin ≤26 whom 80.6% were hospitalized in covid unit, while 134 patients had a measured troponin > 26ng/ ml whom 56.5% were admitted in the ICU (p<0.001) 73% of patients with an admission troponin ≤26ng/L survived while 27% had deceased with p<0.001.Similarly, the measurement of serum Troponin at the of hospitalization was 73ng/L (25.6–319.6) while for discharged patients was 9.6 ng/L (4.3–31.7) The distribution of hs-TnI maximum value measured, showed a concentration significantly higher in the deceased patients vs survivors [200 ng/L IQR 48–651 vs 19 ng/L IQR 7.97–85.87, p<0.001].

our study demonstrates that Troponin may be an indicator of severity and may contribute to determining the severity of patients infected with COVID-19. Utilising troponin measurements alongside with other clinical and laboratory variables can be used for identifying patients at higher risk of in-hospital mortality and there by predict the progression of COVID-19 towards a worse outcome and to assign for more stringent strategies of treatment Competing Interest Statement The authors have declared no competing interest. Funding Statement This study did not receive any funding Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was reviewed retrospectively by the Ethics Committee of the CHU Mohammed VI of Oujda, affiliated with the Centre Hospitalier Universitaire Mohammed VI, Oujda, Morocco. The committee determined that the study did not require formal ethical approval because it was based exclusively on anonymized, routine data collected as part of standard care. Ethical oversight was therefore waived. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript